Langenbahn, Donna
Matsuzawa, Yuka
Lee, Yuen Shan Christine
Fraser, Felicia
Penzien, Donald B.
Simon, Naomi M
Lipton, Richard B.
Minen, Mia T.
Funding for this research was provided by:
Doris Duke Charitable Foundation (Fund to Retain Clinical Scientists)
National Center for Complementary and Integrative Health (K23 AT009706‐01)
Article History
Received: 14 August 2020
Accepted: 21 December 2020
First Online: 1 February 2021
Compliance with Ethical Standards
:
: Dr. Langenbahn reports no disclosures. Dr. Matsuzawa reports no disclosures. Dr. Lee reports no disclosures. Dr. Fraser reports no disclosures. Dr. Penzien reports no disclosures. Dr. Simon reports research grants from the American Foundation for Suicide Prevention, Department of Defense, PCORI, Highland Street Foundation, NIH, and Janssen; speaking and consulting with Vanda Pharmaceuticals Inc., MGH Psychiatry Academy, Axovant Sciences, Springworks, Praxis Therapeutics, Aptinyx, Genomind, Wiley (Deputy Editor, <i>Depression and Anxiety</i>); Equity <i>Spouse:</i> G1 Therapeutics; and royalties from Wolters Kluwer. Dr. Lipton receives research support from the NIH, Migraine Research Foundation and National Headache Foundation. He serves on the editorial board of <i>Neurology</i>, senior advisor to <i>Headache</i>, and associate editor to <i>Cephalalgia</i>. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from American Academy of Neurology, Allergan, American Headache Society, Amgen, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s (Promius), Electrocore, Eli Lilly, eNeura Therapeutics, Equinox, GlaxoSmithKline, Grifols, Lundbeck (Alder), Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff’s Headache 7th and 8th Edition, Oxford Press University, 2009, Wiley and Informa. Dr. Minen reports no disclosures.
Free to read: This content has been made available to all.